Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
- PMID:16282346
- DOI: 10.1182/blood-2005-05-2118
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
Abstract
We explored the ability of the proteasome inhibitor bortezomib, which prevents nuclear factor kappaB (NF-kappaB) activation, to block T-cell activation, proliferation, and survival within alloreactive compared with resting T cells. For this purpose, T cells were stimulated with PHA, alphaCD3/alphaCD28, or allogeneic dendritic cells or through mixed lymphocyte cultures. NF-kappaB expression increased in activated T lymphocytes compared with resting T cells. Of interest, the higher the NF-kappaB expression, the more intense the proliferative blockade induced by bortezomib. Moreover, after mixed lymphocyte reaction (MLR) cultures, alloreactive T cells were 2 logs more sensitive to bortezomib-induced apoptosis than the resting T-cell counterpart. This effect was due to a selective induction of apoptosis among activated T cells that was related to caspase activation and cleavage of the antiapoptotic bcl-2 protein and was partially abolished by the addition of the pancaspase inhibitor Z-VAD-FMK. In addition, after secondary MLR, the number of activated T cells was significantly reduced among T lymphocytes previously cultured with bortezomib when cells from the same donor were used as stimulating cells. By contrast, when third-party donor cells were used as stimulating cells, no significant differences were observed between T lymphocytes previously exposed or not to the drug, indicating a highly specific depletion of T lymphocytes alloreactive against primary donor antigens. The addition of bortezomib decreased not only the proliferation and viability of activated T lymphocytes but also the levels of IFNgamma and IL-2, which were significantly decreased among activated T cells cultured with bortezomib at doses ranging from 10 to 100 nM. In conclusion, at concentrations reached in the clinical setting, bortezomib induces selective apoptosis and decreases Th1 response among alloreactive T lymphocytes while it barely affects unstimulated T cells. These results establish the basis for the clinical use of bortezomib in the management of graft-versus-host disease (GVHD).
Similar articles
- Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.Liu W, Ren HY, Dong YJ, Wang LH, Yin Y, Li Y, Qiu ZX, Cen XN, Shi YJ.Liu W, et al.Int J Hematol. 2012 Dec;96(6):764-72. doi: 10.1007/s12185-012-1195-6. Epub 2012 Nov 23.Int J Hematol. 2012.PMID:23179902
- The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.van der Heijden JW, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G.van der Heijden JW, et al.Clin Exp Rheumatol. 2009 Jan-Feb;27(1):92-8.Clin Exp Rheumatol. 2009.PMID:19327235
- Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ.Sun K, et al.Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5. doi: 10.1073/pnas.0401563101. Epub 2004 May 17.Proc Natl Acad Sci U S A. 2004.PMID:15148407Free PMC article.
- Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.Blanco B, Sánchez-Abarca LI, Caballero-Velázquez T, Santamaría C, Inogés S, Pérez-Simón JA.Blanco B, et al.Leuk Res. 2011 Oct;35(10):1412-5. doi: 10.1016/j.leukres.2011.05.018. Epub 2011 Jun 11.Leuk Res. 2011.PMID:21658766
- Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Cossío S, Hernández-Campo P, Díez-Campelo M, Herrero-Sanchez C, Rodriguez-Serrano C, Santamaría C, Sánchez-Guijo FM, Del Cañizo C, San Miguel JF.Blanco B, et al.Haematologica. 2009 Jul;94(7):975-83. doi: 10.3324/haematol.2008.005017. Epub 2009 Jun 8.Haematologica. 2009.PMID:19508976Free PMC article.
Cited by
- Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.Schütz C, Oelke M, Schneck JP, Mackensen A, Fleck M.Schütz C, et al.Immunotherapy. 2010 Jul;2(4):539-50. doi: 10.2217/imt.10.26.Immunotherapy. 2010.PMID:20636007Free PMC article.Review.
- Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients.Kwun J, Burghuber C, Manook M, Iwakoshi N, Gibby A, Hong JJ, Knechtle S.Kwun J, et al.J Am Soc Nephrol. 2017 Jul;28(7):1991-1996. doi: 10.1681/ASN.2016070727. Epub 2017 Feb 23.J Am Soc Nephrol. 2017.PMID:28232617Free PMC article.
- Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.Rodriguez N, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi P, Giralt S, Perales MA, Sauter C, Ponce DM.Rodriguez N, et al.Transplant Cell Ther. 2021 Nov;27(11):920.e1-920.e9. doi: 10.1016/j.jtct.2021.05.008. Epub 2021 May 21.Transplant Cell Ther. 2021.PMID:34029766Free PMC article.
- A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ, Armand P, Cutler CS, Ho VT, Glotzbecker B, Nikiforow S, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP 3rd.Koreth J, et al.Biol Blood Marrow Transplant. 2015 Nov;21(11):1907-13. doi: 10.1016/j.bbmt.2015.05.027. Epub 2015 Jun 6.Biol Blood Marrow Transplant. 2015.PMID:26055298Free PMC article.Clinical Trial.
- Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.Nakane T, Okamura H, Tagaito Y, Koh S, Yoshimura T, Makuuchi Y, Nanno S, Nakamae M, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H.Nakane T, et al.Int J Hematol. 2019 Dec;110(6):736-742. doi: 10.1007/s12185-019-02743-6. Epub 2019 Sep 27.Int J Hematol. 2019.PMID:31560116Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources